Inventor · disambiguated record
Kyle S. Jones
Also filed as: JONES KYLE · JONES KYLE S
21 granted patents·15 pending applications·118 citations·filing 2013–2025
93Inventor score
Top patents by PatentIndex Score
36 records- 0197US9045541B2CD47 antibodies and methods of use thereofINHIBRX LLC·Filed 2013·Granted Jun 2, 2015·78 cites·21 claims
- 0295US9663575B2CD47 antibodies and methods of use thereofINHIBRX LP·Filed 2015·Granted May 30, 2017·22 cites·22 claims
- 0388US10501551B2Multivalent and multispecific 41BB-binding fusion proteinsINHIBRX INC·Filed 2017·Granted Dec 10, 2019·7 cites·64 claims
- 0487US11560428B2CD33-binding polypeptides and uses thereofINHIBRX INC·Filed 2020·Granted Jan 24, 2023·2 cites·37 claims
- 0586US12331126B2OX40-binding polypeptides and uses thereofINHIBRX BIOSCIENCES INC·Filed 2024·Granted Jun 17, 2025·0 cites·47 claims
- 0684US11117972B2Multivalent and multispecific OX40-binding fusion proteinsINHIBRX INC·Filed 2019·Granted Sep 14, 2021·2 cites·20 claims
- 0784US10093742B2Multispecific GITR-binding fusion proteins and methods of use thereofINHIBRX INC·Filed 2016·Granted Oct 9, 2018·4 cites·57 claims
- 0884US2025250349A1Uses of pdl1-binding proteinsINHIBRX BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 0983US10308720B2Multivalent and multispecific DR5-binding fusion proteinsINHIBRX INC·Filed 2016·Granted Jun 4, 2019·3 cites·24 claims
- 1083US2024376220A1Multivalent and Multispecific DR5-Binding Fusion ProteinsINHIBRX BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 1181US12187804B2Multivalent and multispecific 41BB-binding proteinsINHIBRX BIOSCIENCES INC·Filed 2022·Granted Jan 7, 2025·0 cites·12 claims
- 1278US12012459B2OX40-binding polypeptides and uses thereofINHIBRX INC·Filed 2022·Granted Jun 18, 2024·0 cites·39 claims
- 1377US2025059279A1CD33-Binding Polypeptides and Uses ThereofINHIBRX BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 1476US11976126B2Multivalent and multispecific DR5-binding fusion proteins and methods of modulating immune cellsINHIBRX INC·Filed 2021·Granted May 7, 2024·0 cites·24 claims
- 1575US2025092137A1Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the sameINHIBRX BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 1673US12084502B2CD33-binding polypeptides and uses thereofINHIBRX BIOSCIENCES INC·Filed 2022·Granted Sep 10, 2024·0 cites·27 claims
- 1773US2024166744A1Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereofINHIBRX INC·Filed 2023·Application pending·0 cites
- 1872US12227584B2Multivalent and multispecific OX40-binding fusion proteinsINHIBRX BIOSCIENCES INC·Filed 2021·Granted Feb 18, 2025·0 cites·18 claims
- 1971US11566078B2PDL1-binding proteinsINHIBRX INC·Filed 2019·Granted Jan 31, 2023·0 cites·22 claims
- 2071US2021317205A1Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereofINHIBRX INC·Filed 2021·Application pending·0 cites
- 2170US11447556B2OX40-binding polypeptides and uses thereofINHIBRX INC·Filed 2019·Granted Sep 20, 2022·0 cites·60 claims
- 2270US11117973B2Multivalent and multispecific DR5-binding fusion proteins and methods of treating neoplasmsINHIBRX INC·Filed 2019·Granted Sep 14, 2021·0 cites·39 claims
- 2369US12234297B2IgE binding proteins and uses thereofPHYLAXIS BIOSCIENCE LLC·Filed 2024·Granted Feb 25, 2025·0 cites·30 claims
- 2466US11919963B2CD123-binding polypeptides and uses thereofINHIBRX INC·Filed 2022·Granted Mar 5, 2024·0 cites·28 claims
- 2563US10844129B2Multivalent and multispecific glucocorticoid-induced TNFR-related protein (GITR)-binding single-domain antibody fusion proteins and encoding nucleic acidsINHIBRX INC·Filed 2018·Granted Nov 24, 2020·0 cites·34 claims
- 2659US12195533B2Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the sameINHIBRX BIOSCIENCES INC·Filed 2019·Granted Jan 14, 2025·0 cites·27 claims
- 2759US11434297B2CD123-binding polypeptides and uses thereofINHIBRX INC·Filed 2020·Granted Sep 6, 2022·0 cites·30 claims
- 2859US2025066477A1Gamma Delta T-Cell-Binding Polypeptides and Uses ThereofINHIBRX BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2959US2025109203A1Gamma Delta T-Cell-Targeted Modified IL-2 Polypeptides and Uses ThereofINHIBRX BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3056US2016251435A1Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereofINHIBRX LLC·Filed 2015·Application pending·0 cites
- 3153US2014140989A1Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use ThereofINHIBRX LLC·Filed 2013·Application pending·0 cites
- 3251US2017320958A1Multivalent and multispecific gitr-binding fusion proteinsINHIBRX LP·Filed 2017·Application pending·0 cites
- 3350US2022315638A1Cd123 targeted immunotherapies2SEVENTY BIO INC·Filed 2020·Application pending·0 cites
- 3449US2017198051A1Multivalent and multispecific ox40-binding fusion proteinsINHIBRX LP·Filed 2017·Application pending·0 cites
- 3547US2025163186A1IgE BINDING PROTEINS AND USES THEREOFPHYLAXIS BIOSCIENCE LLC·Filed 2025·Application pending·0 cites
- 3641US2023124851A1B7h3 single domain antibodies and therapeutic compositions thereofINHIBRX LNC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Kyle S. Jones files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →